Novo Nordisk will more than double shipments of lower doses of its obesity drug Wegovy to the U.S. compared with previous months, Chief Executive Officer Lars Fruergaard Jorgensen said Wednesday, as the Danish drugmaker ramps up production of this popular therapy.